A Phase IIIb, Open-label, Multi-center Study to Evaluate the Immunogenicity and Safety of a Booster Dose and Describe the Immune Persistence of MenACYW Conjugate Vaccine With 5- and/or 10-year Booster Doses in Children and Adolescents Who Had Been Primed With MenACYW Conjugate Vaccine as Toddlers
Latest Information Update: 17 Jun 2024
Price :
$35 *
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
- 27 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 09 Feb 2023 Planned primary completion date changed from 3 Feb 2023 to 3 Mar 2023.
- 15 Sep 2022 Planned primary completion date changed from 31 Dec 2022 to 3 Feb 2023.